Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 4:30 PM EDTCARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), today reported financial results for the second quarter of 2015.
"We recently reported positive Phase I results for PRX-106 (oral Anti-TNF), with exciting results showing biological activity in the gut and activation of regulatory T cells," said Moshe Manor, Protalix's President and Chief Executive Officer. "We look forward to selecting an indication and moving this program into a proof of concept trial around year-end. Additionally, we anticipate interim results for PRX-102 for the... More
